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Abstract
Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, 
this area of research has a solid scientific foundation. More than 30 years ago, Folkman found a 
revolutionary new way to think about cancer. He postulated that in order to survive and grow, 
tumors require blood vessels and that by cutting off the blood supply a cancer could be starved 
into remission. Several clinical studies have shown a positive correlation between the number 
of vessels in the tumor, metastasis formation and prognosis. The genetic instability of tumor 
cells permits the occurrence of multiple genetic alterations that facilitate tumor progression and 
metastasis, and cell clones with diverse biological aggressiveness may coexist within the same 
tumor. These two properties allow tumors to acquire resistance to cytotoxic agents. Inhibiting 
angiogenesis is a major area of therapeutic development for the treatment of cancer. Whereas 
conventional chemotherapy, radiotherapy and immunotherapy are directed against tumor cells, 
anti-angiogenic therapy is aimed at the vasculature of a tumor and will either cause total tumor 
regression or keep tumors in a state of dormancy. Even though numerous compounds inhibit 
angiogenesis, few of them have proved effective in vivo, and only a couple of agents have been 
able to induce tumor regression. Bevacizumab is considered to be the first specific angiogenesis 
inhibitor for clinical oncology.
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Introduction
In 1945, Algire and Chalkley were the first to appreciate that growing malignant 
tumors could continuously elicit new capillary growth from the host (Algire and 
Chalkley, 1945). In 1971, Judah Folkman isolated the first angiogenic factor, and called 
it “Tumor Angiogenesis Factor” (TAF). He fractioned by gel-filtration on Sephad-
ex G100 the homogenate of a Walker 256 carcinoma and obtained a fraction with a 
strong angiogenic activity with a molecular weight of about 10,000 Dalton, consisting 
of 25% RNA, 10% proteins, 58% carbohydrates, and a lipid residue. Several other low 
molecular weight angiogenic factors were isolated from the Walker 256 carcinoma, 
capable to induce an angiogenic response in vivo when tested on rabbit cornea or 
chick embryo chorioallantoic membrane (CAM), and in vitro on cultured endotheli-
al cells (Folkman et al., 1971). Subsequently, TAF was extracted from several tumor 
cell lines. Starting from the discovery of TAF, other pro-angiogenic molecules have 
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been isolated, namely basic fibroblast growth factor (bFGF)/fibroblast growth fac-
tor-2 (FGF-2), vascular endothelial growth factor (VEGF)/vascular permeability factor 
(VPF), and placental growth factor (PlGF). In the meantime, it has been demonstrated 
the angiogenic activity of non-classic angiogenic molecules, including hematopoietic 
cytokines, namely granulocyte colony stimulating factor (G-CSF), granulocyte mac-
rophage colony stimulating factor (GM-CSF), and erythropoietin (EPO). 
In this context, Folkman (1971) hypothesized that tumor growth is angiogenic-
dependent and that inhibition of angiogenesis could be therapeutic, introducing the 
term anti-angiogenesis. Investigations on neoplastic transformation have focused on 
transformed cells and in the meantime have addressed the tumor microenvironment 
and documented its importance in tumor progression. The pathogenesis of most can-
cers, in fact, includes complex and mutual interactions affecting tumor cells, inflam-
matory cells and various components of the extracellular matrix. These concepts are 
now widely accepted and supported by experimental and clinical studies.
Tumor growth occurs through an avascular phase followed by a vascular phase. 
Assuming that such growth is dependent on angiogenesis and that this depends on 
the release of angiogenic factors, the acquisition of an angiogenic ability can be seen 
as an expression of progression from neoplastic transformation to tumor growth and 
metastasis (Ribatti et al., 1999).
Practically all solid tumors, including those of the colon, lung, breast, cervix, blad-
der, prostate and pancreas, progress through these two phases. The role of angiogen-
esis in the growth and survival of leukemias and other hematological malignancies 
has only become evident since 1994, thanks to a series of studies demonstrating that 
progression in several forms is clearly related to their degree of angiogenesis (Vacca 
and Ribatti, 2006).
In the 1970s Gullino’s group (Brem et al., 1977, 1978; Maiorana and Gullino, 1978) 
observed that experimental breast cancer in rat and mouse gave rise to marked breast 
angiogenic activity that was lacking in adult gland. Moreover, just like the hyper-
plastic and dysplastic breast lesions more frequently subject to malignant change, 
pre-malignant lesions also induce a strong vasoproliferative response long before any 
morphological sign of malignant transformation can be observed.
The avascular phase appears to correspond to the histopathological picture pre-
sented by a small colony of neoplastic cells (500,000–1 million cells/1–2mm in diam-
eter) that reaches a steady state before it proliferates and becomes rapidly invasive. 
Here metabolites and catabolites are transferred by simple diffusion through the 
surrounding tissue. The cells at the periphery of the tumor continue to reproduce, 
whereas those in the deeper portion die away. Some of these prevascular lesions can 
be seen in the skin or in the bladder, but the majority of prevascular tumors in the 
breast, colon, and other organs are microscopic, clinically undetectable, and asympto-
matic.
Tumor angiogenesis may occur through several mechanisms: i) sprouting angio-
genesis; ii) recruitment of bone marrow-derived endothelial progenitor cells to form 
new vessels (postnatal vasculogenesis) ; iii) vasculogenic mimicry (the transdifferen-
tiation of cancer cells allowing them to form tubular structures themselves); iv) mosa-
ic vessel formation (the incorporation of cancer cells into the vessel wall or vascular 
cooption);v) intussusception.
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Morphofunctional properties of tumor blood vessels
In tumors, the organ- and tissue-specific vascular architecture is not retained. 
Tumor blood vessels are irregular in size, shape, and branching pattern, lack the nor-
mal hierarchy, and do not display recognizable features of arterioles, capillaries, or 
venules (Ribatti et al., 2007a). Tumor-associated endothelium is structurally defective: 
intercellular gaps, transendothelial holes, vesiculo-vacuolar organelles, and endothe-
lial fenestrae are present in the endothelium of tumor vessels (Dvorak et al., 1988). 
Defects in endothelial cell barrier function, due to abnormal cell–cell junctions and 
other changes, are responsible of vascular leakiness, which has been attributed also to 
highly active angiogenesis and microvascular remodeling. Leakiness correlates with 
histological grade and malignant potential (Doldrup et al., 1998) and can be exploited 
in locating tumors by imaging contrast media and in the delivery of macromolecular 
therapeutics (Mc Donald and Choyke, 2003). Furthermore, it results in extravasation 
of plasma proteins and even erythrocytes and may facilitate the traffic of tumor cells 
into the bloodstream and the formation of metastases (Doldrup et al., 1998). Whereas 
endothelial cells of mature, quiescent vessels are characteristically low proliferative 
and their estimated turnover times are measured in years, those of tumor vessels are 
markedly dependent on growth factors for survival. VEGF plays a central role in the 
induction of host vessels into a growing tumor. When endothelial cells invade a new-
ly formed tumor, they come into contact with tumor cells that produce VEGF, which 
may be responsible not only for vascular proliferation but also for the altered perme-
ability of the newly formed vessels (Senger et al., 1995; Dvorak et al., 1987). Although 
tumor cells represent the major source of VEGF, tumor-associated stroma is also an 
important site of VEGF production (Fukumura et al., 1998).
In tumors, pericytes are located near blood vessels at the growing front of tumors, 
where angiogenesis is most active, and show morphological abnormalities (Morikawa 
et al., 2002). Moreover, pericyte deficiency may be partly responsible for vessel abnor-
malities in tumor blood vessels (Gerhardt and Semb, 2008) and partial dissociation of 
pericytes (Hobbs et al., 1998; Hashizume et al., 2000) contributes to increased tumor 
vascular permeability.
Inflammation and tumor angiogenesis
Rudolf Virchow in 1863 critically recognized for the first time the presence of 
inflammatory cells infiltrating neoplastic tissues and first established a causative con-
nection between the “lymphoreticular infiltrate” at sites of chronic inflammation and 
the development of cancer. 
In 1986, Dvorak noted that wound healing and tumor stroma formation shared 
many important properties (Dvorak, 1986). They both were rich of newly formed 
vessels and fibrin matrix. He likened tumors to “wounds that do not heal”, because 
tumor cells secreted a vascular permeability factor, now referred to as VEGF, that 
could lead to persistent extravasation of fibrin and fibronectin and continuous gener-
ation of extracellular matrix. It is well established that tumor cells are able to secrete 
pro-angiogenic and pro-inflammatory factors as well as mediators for inflammatory 
cells. They produce indeed cytokines such as VEGF, FGF-2, interleukin-8 (IL-8), PlGF, 
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transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), 
angiopoietins (Angs) and others. These are exported from tumor cells or mobilized 
from the extracellular matrix. As a consequence, tumor cells are surrounded by an 
infiltrate of inflammatory cells, namely lymphocytes, neutrophils, macrophages and 
mast cells. These cells communicate via a complex network of intercellular signaling 
pathways, mediated by surface adhesion molecules, cytokines and their receptors. 
Results point to the importance of a cross-talk between several host cells for promot-
ing angiogenic effects in tumor areas. 
Inflammatory cells cooperate and synergise with stromal cells as well as malig-
nant cells in stimulating endothelial cell proliferation and blood vessel formation. 
These synergies may represent important mechanisms for tumor development and 
metastasis by providing efficient vascular supply and easy pathway to escape host 
defense. Indeed, the most aggressive human cancers, such as malignant melanoma, 
breast carcinoma and colorectal adenocarcinoma, are associated with a dramatic 
host response composed of various inflammatory cells, especially macrophages and 
mast cells. It is well known that tumor vessels present a defective organization of the 
endothelium.
The angiogenic switch and the concept of normalization
Angiogenesis is controlled by the balance between molecules that have posi-
tive and negative regulatory activities and this concept has led to the notion of the 
angiogenic switch, which depends on an increased production of one or more posi-
tive regulators of angiogenesis (Ribatti et al., 2007b). Most human tumors arise and 
remain in situ without angiogenesis for a long time before switching to an angio-
genic phenotype, through a pre-neoplastic stage as occurs in breast and cervical 
carcinomas, which becomes neovascularized before the malignant tumor appears. 
Activation of the angiogenic switch has been attributed to the synthesis or release of 
angiogenic factors, and accordingly to the balance hypothesis the level of angiogen-
esis inducers and inhibitors regulates angiogenesis in physiological conditions. This 
balance is altered in pathological conditions, including  tumors, as a consequence of 
an increased bioavailability or activity of the inducer proteins, or reduced concentra-
tions of endogenous angiogenesis inhibitors. Thrombospondin-1(TSP-1) was the first 
endogenous inhibitor for which there was compelling evidence of participation in 
the angiogenic switch, because it was down-regulated in tumors before angiogenesis 
could be triggered. By 1989, the switch itself was understood as the result of a shift in 
the ‘net balance’ of angiogenesis stimulators and inhibitors. This led to the discovery 
of angiostatin and endostatin. Angiostatin is a 38-kDa internal fragment of plasmino-
gen, while endostatin is a 20-kDa internal fragment of collagen XVIII.
In the RIP-TAG transgenic mice expressing an oncogene in beta cells of the pan-
creas, Folkman et al. (1989) found that the angiogenic switch occurs in the early stage 
of cancerogenesis in hyperplastic islets before the onset of the tumor formation.
Restore of this balance may induce a normalization of structure of blood vessels. 
The concept of “normalization” of tumor blood vessels by anti-angiogenic drugs was 
introduced by Rakesh Jain in 2001 (Jain, 2001).The state of normalization is probably 
transient and dependent on the dose and duration of the treatment.
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Anti-angiogenesis
Anti-angiogenic agents may be divided in two major groups: indirect agents that 
block the expression or the activity of angiogenic molecules or the expression of their 
receptors on endothelial cells, and agents able to directly affect endothelial cell func-
tion or survival. Beginning in the 1980s, the industry began exploiting the field of 
anti-angiogenesis for creating new therapeutic molecules in angiogenesis-dependent 
diseases. At present anti-angiogenic therapy is essentially anti-VEGF/VEGF receptor 
(VEGFR) therapy and has already fulfilled its promise in the clinic.
Bevacizumab (Avastin) was the first angiogenesis inhibitor approved by the 
Food and Drug Adminstration (FDA) for the treatment of colorectal cancer in Feb-
ruary 2004, administered in combination with irinotecan, 5-fluorouracil and leucovi-
rin (Hurwitz et al., 2004). It was subsequently approved for use, in combination with 
cytotoxic chemotherapy, in other cancers including non-small-cell lung cancer and 
breast cancer, demonstrating an improvement in overall survival or delayed tumor 
progression compared to chemotherapy alone (Sandler et al., 2006; Miller et al., 2007).
Encouraging results have also been obtained when chemotherapy has been used 
in combination with an anti-VEGF2 monoclonal antibody (cediranib; Goss et al., 
2010) and an oral tyrosine kinase inhibitor of VEGFRs and epidermal growth factor 
receptor (EGFR) (vandetanib). The observation that combining chemotherapy with 
angiogenesis inhibitors causes increased apoptosis in tumors in vivo (Song et al., 
2001; Inoue et al., 2003) suggests that angiogenesis inhibitors may have an additive 
effect when administered in combination with chemotherapy.
Removal of VEGF inhibition causes tumor re-growth due to the fact that pericytes 
provide a scaffold for the rapidly re-growing of tumor vessels (Mancuso et al., 2006). 
Pericytes have been indicated as putative targets in the pharmacological therapy of 
tumors by using the synergistic effect of anti-endothelial and anti-pericytic molecules. 
Removal of pericyte coverage leads to exposed tumor vessels, which may explain the 
enhanced effect of combining inhibitors that target both tumor vessels and pericytes. 
Bergers et al. (2003) showed that combined treatment or pre-treatment with anti-
PDGF-B/PDGF receptor beta (PDGFR-β), reducing pericyte coverage, increases the 
success of anti-VEGF treatment in the mouse RIP1-TAG2 model.
A clinical challenge in anti-angiogenesis is the finding of biological markers that 
help to identify subsets of patients more likely to respond to a given anti-angiogenic 
therapy, to detect early clinical benefit or emerging resistances and to decide whether 
to change therapy in second-line treatments (Table 1).
The results from clinical trials have not shown the dramatic antitumor effects 
that were expected following preclinical studies, which revealed a much higher effi-
cacy of these type of agent in animal models. Patients with different types of tumors 
respond differently to anti-angiogenic therapy. While colorectal, lung and breast 
cancer patients have responded, pancreatic cancer patients have not shown survival 
advantage when treated with anti-angiogenic monotherapy or combinations of anti-
angiogenic agents with chemotherapy. Additionally, preclinical and clinical data have 
shown the possibility that tumors may acquire resistance to anti-angiogenic drugs or 
may escape anti-angiogenic therapy via compensatory mechanisms. Most of the FDA-
approved drugs, as well as those in phase III clinical trials, target a single proangio-
genic protein. However, multiple angiogenic molecules may be produced by tumors, 
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and tumors at different stages of development may depend on different angiogenic 
factors for their blood supply. Therefore, blocking a single angiogenic molecule might 
have little or no impact on tumor growth. Cancer genomics and proteomics are likely 
to identify novel, tumor-specific endothelial targets and accelerate drug discovery.
Ligand-targeted therapeutic strategies
Since tumor endothelial cells express several markers that are not expressed in nor-
mal counterpart, it is possible to develop ligand-targeted chemotherapeutic strategies, 
based on peptides that are selective for tumor vasculature and involving vascular tar-
geting agents (VTAs) or vascular disrupting agents (VDAs) (Spear et al., 2011). VTAs/
VDAs directly attack the tumor endothelial cells and inhibit their proliferation and 
the destruction of existing tumor blood vessels results in tumor hypoxia and tumor 
cell necrosis. VDAs comprise two main classes: (1) small-molecules, that localize to 
the tumor endothelium by exploiting the known differences between tumor and nor-
mal endothelium to induce selective vascular dysfunction, and (2) ligand-based thera-
pies, chemotherapeutics, toxins, procoagulant and proapoptotic effectors to the tumor 
endothelium (Siemann et al., 2004; Thorpe, 2004; Pilat and Lorusso, 2006).
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Table 1 – Predictive markers useful to identify subsets of patients more responsive to anti-angiogenic therapy.
Plasma and/or urinary levels of angiogenic cytokines
Circulating platelet levels
Serum levels of soluble VEGFRs
Serum levels of soluble v-CAM, E-selectin, and Tie-2
Circulating levels of endothelial precursor cells (EPCs) and endothelial cells (CECs)*
Immunohistochemical expression of thymidine phosphorylase (TP) in endothelial cells**
Cancer stem cells (CSCs) detection***
Functional imaging of tumor angiogenesis [single positron emission tomography (SPECT) 
and positron emission tomography)]****
* In general, but not always, the plasma level of the markers decrease parallel to tumor regression in 
response to the therapy, and the circulating levels of one or more of these factors has been reported as an 
indicator to predict patient survival.
** TP-positive endothelial cells correlate with CD34-positive endothelial cells and microvascular density in 
tumor bioptic specimens. Moreover, TP expression correlates with a better survival rate of patients.
*** CSCs secrete high levels of angiogenic cytokines and are more resistant to conventional chemotherapy 
and radiotherapy due to an increased expression of antiapoptotic proteins.
**** Imaging techniques allow an estimation on tumor angiogenesis and of the effect of anti-angiogenic 
therapy on tumor microcirculation.
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